New drug shows promise for anemia in diabetic kidney patients
NCT ID NCT07359027
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how well the drug Roxadustat works for anemia in people with diabetic kidney disease stages 3-4. 124 participants took the drug for 24 weeks, and researchers measured changes in hemoglobin and iron levels. The goal was to see if the drug can safely raise red blood cell counts in this specific group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Roxadustat (a drug taken as capsules to boost red blood cell production)
What this could lead to
If it works, this could offer a new way to manage anemia in people with diabetic kidney disease, potentially reducing the need for blood transfusions or other treatments.
What could go wrong
This is a small, single-arm, phase 4 study with no placebo group, so results may not be definitive. The drug may cause side effects like high blood pressure or blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Second Xiangya Hospital, Central South University
Changsha, 410000, China